Credit: Getty Images This review provides a concise overview of the epidemiology, etiology, history, diagnostic criteria, and management of CMV infection in solid organ transplant recipients.

Letermovir (Prevymis) proved noninferior to valganciclovir (Valcyte), the standard of care, in a clinical trial of cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients, ...

Please provide your email address to receive an email when new articles are posted on . Letermovir was first approved in 2017 for high-risk stem cell transplant recipients. CMV is relatively common in ...

Livtencity is an orally bioavailable anti-CMV compound that targets and inhibits the UL97 protein kinase and its natural substrates. The Food and Drug Administration (FDA) has approved Livtencity ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Letermovir effectively prevented cytomegalovirus disease among kidney transplant patients with ...

Letermovir appears to be better tolerated than the current standard of care, valganciclovir, a prodrug of ganciclovir, which frequently causes myelosuppression. The FDA has approved the antiviral ...

Credit: Getty Images. The NDA submission is supported by data from the multicenter, randomized, open-label, active-controlled phase 3 TAK-620-303 (SOLSTICE) trial. The Food and Drug Administration ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the United States commercial availability of LIVTENCITY™ (maribavir), the first ...

A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma Alemtuzumab appears ...

Allogeneic hematopoietic stem cell transplantation (SCT) is a procedure in which the bone marrow from a healthy donor is used to reconstitute the hematopoietic system (including the cells of the ...